Literature DB >> 25063884

Monoclonal antibody targeting chikungunya virus envelope 1 protein inhibits virus release.

Promsin Masrinoul1, Orapim Puiprom1, Atsushi Tanaka2, Miwa Kuwahara3, Panjaporn Chaichana1, Kazuyoshi Ikuta2, Pongrama Ramasoota4, Tamaki Okabayashi5.   

Abstract

Chikungunya virus (CHIKV) causes an acute clinical illness characterized by sudden high fever, intense joint pain, and skin rash. Recent outbreaks of chikungunya disease in Africa and Asia are a major public health concern; however, there is currently no effective licensed vaccine or specific treatment. This study reported the development of a mouse monoclonal antibody (MAb), CK47, which recognizes domain III within the viral envelope 1 protein and inhibited the viral release process, thereby preventing the production of progeny virus. The MAb had no effect on virus entry and replication processes. Thus, CK47 may be a useful tool for studying the mechanisms underlying CHIKV release and may show potential as a therapeutic agent.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chikungunya virus; Monoclonal antibody; Post-entry inhibitory step

Mesh：

Substances：

Year:  2014        PMID： 25063884     DOI： 10.1016/j.virol.2014.05.038

Source DB:  PubMed          Journal:  Virology        ISSN： 0042-6822            Impact factor:   3.616


  25 in total

1.  Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus.

Authors:  Scott A Smith; Laurie A Silva; Julie M Fox; Andrew I Flyak; Nurgun Kose; Gopal Sapparapu; Solomiia Khomandiak; Solomiia Khomadiak; Alison W Ashbrook; Kristen M Kahle; Rachel H Fong; Sherri Swayne; Benjamin J Doranz; Charles E McGee; Mark T Heise; Pankaj Pal; James D Brien; S Kyle Austin; Michael S Diamond; Terence S Dermody; James E Crowe
Journal:  Cell Host Microbe       Date:  2015-07-08       Impact factor: 21.023

2.  Monoclonal Antibodies as Prophylactic and Therapeutic Agents Against Chikungunya Virus.

Authors:  April M Clayton
Journal:  J Infect Dis       Date:  2016-12-15       Impact factor: 5.226

Review 3.  Inhibitory Antibodies Targeting Emerging Viruses: Advancements and Mechanisms.

Authors:  Jing Jin; Graham Simmons
Journal:  Clin Vaccine Immunol       Date:  2016-07-05

4.  Host ESCRT factors are recruited during chikungunya virus infection and are required for the intracellular viral replication cycle.

Authors:  Shiho Torii; Yasuko Orba; Michihito Sasaki; Koshiro Tabata; Yuji Wada; Michael Carr; Jody Hobson-Peters; Roy A Hall; Ayato Takada; Takasuke Fukuhara; Yoshiharu Matsuura; William W Hall; Hirofumi Sawa
Journal:  J Biol Chem       Date:  2020-04-27       Impact factor: 5.157

Review 5.  Vaccine and Therapeutic Options To Control Chikungunya Virus.

Authors:  Ann M Powers
Journal:  Clin Microbiol Rev       Date:  2017-12-13       Impact factor: 26.132

6.  Neutralizing Monoclonal Antibodies Block Chikungunya Virus Entry and Release by Targeting an Epitope Critical to Viral Pathogenesis.

Authors:  Jing Jin; Nathan M Liss; Dong-Hua Chen; Maofu Liao; Julie M Fox; Raeann M Shimak; Rachel H Fong; Daniel Chafets; Sonia Bakkour; Sheila Keating; Marina E Fomin; Marcus O Muench; Michael B Sherman; Benjamin J Doranz; Michael S Diamond; Graham Simmons
Journal:  Cell Rep       Date:  2015-12-10       Impact factor: 9.423

7.  Optimal therapeutic activity of monoclonal antibodies against chikungunya virus requires Fc-FcγR interaction on monocytes.

Authors:  Julie M Fox; Vicky Roy; Bronwyn M Gunn; Ling Huang; Melissa A Edeling; Matthias Mack; Daved H Fremont; Benjamin J Doranz; Syd Johnson; Galit Alter; Michael S Diamond
Journal:  Sci Immunol       Date:  2019-02-22

Review 8.  Immune-Mediated Protection and Pathogenesis of Chikungunya Virus.

Authors:  Julie M Fox; Michael S Diamond
Journal:  J Immunol       Date:  2016-12-01       Impact factor: 5.422

9.  Neutralizing Antibodies Inhibit Chikungunya Virus Budding at the Plasma Membrane.

Authors:  Jing Jin; Jesús G Galaz-Montoya; Michael B Sherman; Stella Y Sun; Cynthia S Goldsmith; Eileen T O'Toole; Larry Ackerman; Lars-Anders Carlson; Scott C Weaver; Wah Chiu; Graham Simmons
Journal:  Cell Host Microbe       Date:  2018-08-23       Impact factor: 21.023

10.  A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis.

Authors:  Shirley Lam; Min Nyo; Patchara Phuektes; Chow Wenn Yew; Yee Joo Tan; Justin Jang Hann Chu
Journal:  MAbs       Date:  2015-08-25       Impact factor: 5.857
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.